Gland Pharma Reports 47% Profit Growth and Signs Five-Year CDMO Agreement
Gland Pharma reported a 47% year-on-year rise in consolidated net profit to Rs 317 crore for Q1 FY27, driven by a 20% increase in revenue to Rs 1,800 crore. Growth was supported by strong performance in the CDMO and B2B segments, with significant contributions from the US and Europe markets. The company announced a five-year strategic manufacturing and supply agreement with a global pharmaceutical firm for sterile injectable products, expected to start generating revenue from 2029. Investments in technology and capacity expansions aim to sustain long-term growth.
First-hand measurement across 8 sources
We measured how 8 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is positive (68/100). Lens Score 35/100.
Outlets measured: freepressjournal, economictimes, businessstandard, thehindu, businessstandard, mint, businessstandard, economictimes. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (55–75/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
economictimes broke this story on 9 Aug, 05:50 am. Other outlets followed.